CV 9103

Drug Profile

CV 9103

Alternative Names: CV9103; mRNA prostate cancer vaccine - CureVac

Latest Information Update: 04 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureVac
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 04 Oct 2015 No recent reports of development identified - Phase-I for Prostate cancer (Hormone refractory, Metastatic disease) in USA (Intradermal)
  • 04 Oct 2015 No recent reports of development identified - Phase-II for Prostate cancer (Hormone refractory, Metastatic disease) in Italy and Germany (Intradermal)
  • 07 Jul 2015 Updated adverse events and immunogenicity data from a phase I/IIa study in Prostate cancer published in the Journal for ImmunoTherapy of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top